High impactLayoffs

Aura Biosciences Lays Off 20% of Workforce, Overhauls C-Suite in R&D Pivot

NewsData.io · United States · Aug 11, 2026

Boston biotech Aura Biosciences is cutting approximately 20% of its workforce — roughly 22 positions based on its 113 full-time employees as of February — as new CEO Natalie Holles refocuses the company exclusively on ocular oncology. The restructuring carries a severance cost of $2.9M–$3.2M and includes a full C-suite overhaul, with three new executives installed and three departing. The company extended its cash runway to early 2029 as a result of the strategic pullback from bladder cancer research.

Get the weekly brief by email

What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.

Aura BiosciencesBiotechLife SciencesOcular Oncology

Related stories